Cannabis-Derived Sleep Aid Shows Dependence Signs in Mice
A cannabis compound sold as a sleep aid produced signs of dependence in mice after three days of repeated dosing, according to University of Connecticut scientists. The study, appearing in Drug and Alcohol Dependence, found reduced response and withdrawal effects, prompting questions about the product’s safety profile.
University of Connecticut researchers found that a cannabis-derived product marketed for sleep showed indicators of dependence in mice after three days of repeated administration. The study, published in Drug and Alcohol Dependence, reported diminished responsiveness and withdrawal signs, raising questions about how the product’s safety should be assessed.
The available summary does not establish human outcomes. The work sits within wider interest in cannabis-related consumer products sold to improve sleep, where animal findings can inform—but not settle—questions about repeated use and dependence risk.
For people considering cannabis-derived sleep products, the finding may encourage caution about repeated use, though mouse results cannot predict human outcomes. Companies selling such products could face more questions about safety claims, and clinicians may need to discuss dependence risk with patients. Regulators and researchers may treat the study as a prompt for closer evaluation. The societal impact remains uncertain and will depend on further evidence.